TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 140 filers reported holding TRAVERE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,518,058 | -4.7% | 1,512,087 | +63.7% | 0.00% | 0.0% |
| Q2 2023 | $14,190,965 | -20.3% | 923,891 | +16.8% | 0.00% | -25.0% |
| Q1 2023 | $17,794,717 | -68.0% | 791,228 | -70.0% | 0.00% | -66.7% |
| Q4 2022 | $55,522,270 | -11.8% | 2,640,146 | +3.4% | 0.01% | -20.0% |
| Q3 2022 | $62,930,000 | -0.6% | 2,553,974 | -2.2% | 0.02% | +7.1% |
| Q2 2022 | $63,305,000 | -5.2% | 2,612,646 | +0.9% | 0.01% | 0.0% |
| Q1 2022 | $66,747,000 | -17.1% | 2,590,107 | -0.1% | 0.01% | -12.5% |
| Q4 2021 | $80,510,000 | +203.7% | 2,593,757 | +137.2% | 0.02% | +166.7% |
| Q3 2021 | $26,513,000 | -26.0% | 1,093,322 | -55.5% | 0.01% | -25.0% |
| Q2 2021 | $35,852,000 | +73.5% | 2,457,280 | +197.0% | 0.01% | +60.0% |
| Q1 2021 | $20,661,000 | +6.2% | 827,434 | +15.9% | 0.01% | 0.0% |
| Q4 2020 | $19,459,000 | – | 713,966 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |